These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

380 related items for PubMed ID: 20006394

  • 1. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.
    Shim JH, Lee HC, Kim KM, Lim YS, Chung YH, Lee YS, Suh DJ.
    J Hepatol; 2010 Feb; 52(2):176-82. PubMed ID: 20006394
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the efficacies of lamivudine versus entecavir in patients with hepatitis B virus-related decompensated cirrhosis.
    Hyun JJ, Seo YS, Yoon E, Kim TH, Kim DJ, Kang HS, Jung ES, Kim JH, An H, Kim JH, Yim HJ, Yeon JE, Lee HS, Byun KS, Um SH, Kim CD, Ryu HS.
    Liver Int; 2012 Apr; 32(4):656-64. PubMed ID: 22099071
    [Abstract] [Full Text] [Related]

  • 3. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
    Yue-Meng W, Li YH, Wu HM, Yang J, Xu Y, Yang LH, Yang JH.
    Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
    [Abstract] [Full Text] [Related]

  • 4. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ, Shim JH, Lee HC, Yoo DJ, Kim KM, Lim YS, Suh DJ.
    J Gastroenterol Hepatol; 2011 Sep; 26(9):1380-8. PubMed ID: 21884247
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of telbivudine compared with entecavir in hepatitis B virus-related cirrhosis: 2 year follow-up data.
    Kim HR, Yim HJ, Kang S, Suh SJ, Kim SY, Hyun JJ, Koo JS, Kim JH, Seo YS, Yeon JE, Lee SW, Byun KS, Um SH.
    Liver Int; 2015 Mar; 35(3):860-9. PubMed ID: 24905912
    [Abstract] [Full Text] [Related]

  • 6. [Entecavir therapy for patients with hepatitis B virus-related decompensated cirrhosis].
    Kim IS, Mun JI, Koo JH, Kang CJ, Bak JK, Cheong JY, Cho SW.
    Korean J Gastroenterol; 2012 Mar; 59(3):224-31. PubMed ID: 22460571
    [Abstract] [Full Text] [Related]

  • 7. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.
    Ye XG, Su QM.
    World J Gastroenterol; 2013 Oct 21; 19(39):6665-78. PubMed ID: 24151397
    [Abstract] [Full Text] [Related]

  • 8. [Therapeutic efficacy of lamivudine in patients with hepatitis B virus-related decompensated cirrhosis in Korea].
    Jung S, Suh DJ, Park HJ, Park YH, Song HG, Lee HC, Chung YH, Lee YS.
    Taehan Kan Hakhoe Chi; 2002 Dec 21; 8(4):418-27. PubMed ID: 12506246
    [Abstract] [Full Text] [Related]

  • 9. Entecavir therapy in a hepatitis B-related decompensated cirrhotic patient.
    Muneer B, Testa G, Millis JM, Mohanty SR.
    South Med J; 2008 Nov 21; 101(11):1173-6. PubMed ID: 19088536
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice.
    Ridruejo E, Marciano S, Galdame O, Reggiardo MV, Muñoz AE, Adrover R, Cocozzella D, Fernandez N, Estepo C, Mendizabal M, Romero GA, Levi D, Schroder T, Paz S, Fainboim H, Mandó OG, Gadano AC, Silva MO.
    Ann Hepatol; 2014 Nov 21; 13(3):327-36. PubMed ID: 24756007
    [Abstract] [Full Text] [Related]

  • 11. The efficacy and safety of entecavir in patients with advanced schistosomiasis co-infected with hepatitis B virus.
    Huang LH, Qiu YW, Hua HY, Niu XH, Wu PF, Wu HY, Zhu HY, Yang XJ, Yao SZ, Li YG.
    Int J Infect Dis; 2013 Aug 21; 17(8):e606-9. PubMed ID: 23490092
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness of entecavir in chronic hepatitis B NUC-naive patients in routine clinical practice.
    Ridruejo E, Adrover R, Cocozzella D, Reggiardo MV, Estepo C, Schroder T, Paz S, Mendizábal M, Fainboim H, Mandó OG, Silva MO.
    Int J Clin Pract; 2011 Aug 21; 65(8):866-70. PubMed ID: 21762311
    [Abstract] [Full Text] [Related]

  • 13. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
    Kim SS, Hwang JC, Lim SG, Ahn SJ, Cheong JY, Cho SW.
    Am J Gastroenterol; 2014 Aug 21; 109(8):1223-33. PubMed ID: 24890440
    [Abstract] [Full Text] [Related]

  • 14. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM.
    Gastroenterology; 2011 Oct 21; 141(4):1212-9. PubMed ID: 21762659
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy and safety of adefovir dipivoxil in patients with decompensated liver cirrhosis with Lamivudine resistance compared to patients with compensated liver disease].
    Moon W, Choi MS, Moon YM, Paik SW, Lee JH, Koh KC, Yoo BC, Rhee JC, Shim SG.
    Korean J Hepatol; 2005 Jun 21; 11(2):125-34. PubMed ID: 15980671
    [Abstract] [Full Text] [Related]

  • 16. Safety and efficacy of tenofovir in chronic hepatitis B-related decompensated cirrhosis.
    Lee SK, Song MJ, Kim SH, Lee BS, Lee TH, Kang YW, Kim SB, Song IH, Chae HB, Ko SY, Lee JD.
    World J Gastroenterol; 2017 Apr 07; 23(13):2396-2403. PubMed ID: 28428719
    [Abstract] [Full Text] [Related]

  • 17. Long-term impact of entecavir monotherapy in chronic hepatitis B patients with a partial virologic response to entecavir therapy.
    Ko SY, Choe WH, Kwon SY, Kim JH, Seo JW, Kim KH, Lee CH.
    Scand J Gastroenterol; 2012 Nov 07; 47(11):1362-7. PubMed ID: 22934534
    [Abstract] [Full Text] [Related]

  • 18. Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: virological breakthrough is also dependent on adherence to medication.
    Kamezaki H, Kanda T, Wu S, Nakamoto S, Arai M, Maruyama H, Fujiwara K, Imazeki F, Yokosuka O.
    Scand J Gastroenterol; 2011 Sep 07; 46(9):1111-7. PubMed ID: 21623676
    [Abstract] [Full Text] [Related]

  • 19. Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir.
    Pan CQ, Hu KQ, Yu AS, Chen W, Bunchorntavakul C, Reddy KR.
    J Viral Hepat; 2012 Mar 07; 19(3):213-9. PubMed ID: 22329376
    [Abstract] [Full Text] [Related]

  • 20. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years.
    Wong GL, Wong VW, Chan HY, Tse PC, Wong J, Chim AM, Yiu KK, Chu SH, Chan HL.
    Aliment Pharmacol Ther; 2012 Jun 07; 35(11):1326-35. PubMed ID: 22506552
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.